# Antidiabetic Drugs for Steatotic Liver Disease

> **NCT03646292** · PHASE4 · COMPLETED · sponsor: **Yonsei University** · enrollment: 51 (actual)

## Conditions studied

- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Type 2 Diabetes
- Digestive System Disease
- Liver Diseases
- Fatty Liver
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Non-Alcoholic Fatty Liver Disease
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Sodium-Glucose Cotransporter 2 Inhibitors
- Pioglitazone
- Molecular Mechanisms of Pharmacological Action
- Empagliflozin
- Thiazolidinediones

## Interventions

- **DRUG:** Pioglitazone
- **DRUG:** Empagliflozin
- **DRUG:** Combination of pioglitazone and empagliflozin

## Key facts

- **NCT ID:** NCT03646292
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-06
- **Primary completion:** 2022-06-16
- **Final completion:** 2022-06-16
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03646292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03646292, "Antidiabetic Drugs for Steatotic Liver Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03646292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*